TY - JOUR T1 - Safety of granulocyte colony-stimulating factor in normal donors JF - Current Opinion in Hematology Y1 - 2001 A1 - Gutierrez-Delgado,F. A1 - Bensinger,W. KW - *Blood Donors KW - *Granulocyte Colony-Stimulating Factor / ad [Administration & Dosage] KW - *Granulocyte Colony-Stimulating Factor / to [Toxicity] KW - *Hematopoietic Stem Cell Transplantation KW - 143011-72-7 (Granulocyte Colony-Stimulating Factor) KW - Follow-Up Studies KW - Hematopoietic Stem Cell Mobilization / ae [Adverse Effects] KW - Humans AB - Granulocyte colony-stimulating factor (G-CSF), which is widely used to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to the use of PBSC as a major alternative to bone marrow for patients undergoing allogeneic transplants. Safety issues related to the administration of G-CSF to normal donors, however, are still under study. The short-term effects after G-CSF administration are well known and manageable. G-CSF induces a hypercoagulable state, which may predispose certain donors to thrombotic complications. A dose of 10 microg/kg/d for 5 days has been recommended for routine clinical use, but the optimal dose and schedule for PBSC collection are still being defined. Small studies to date have shown no late effects of G-CSF administration but there is insufficient information regarding any long-term adverse effects or risks. Although the administration of G-CSF to normal donors for PBSC collection appears safe, longer follow-up is required. [References: 70] VL - 8 CP - 3 N1 - Gutierrez-Delgado F Bensinger W Review United States Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review ID - 623 ER -